George Katsamakis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

Richard K. Burt, Yvonne Loh, Bruce A. Cohen et al. · The Lancet Neurology · 2009 · 275 citations

Regenerative Medicine, Cell Therapy, Transplantation +11

Autoimmune thyroiditis and a rapidly progressive dementia: Global hypoperfusion on SPECT scanning suggests a possible mechanism

Concetta Forchetti, George Katsamakis, David C. Garron · Neurology · 1997 · 159 citations

The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis

J. Iriarte, George Katsamakis, P. de Castro · Multiple Sclerosis Journal · 1999 · 112 citations

Neurological Disorder, Useful Tool, Diagnosis +17

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

Claudia Kaiser, D. K. Shukla, Glenn T. Stebbins et al. · Journal of Neuroimmunology · 2009 · 66 citations

Disease Progression, Neurological Disorder, Clinical Trials +4